Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Does Rachel Sherman Think About Top FDA Regulatory Issues?

Executive Summary

Speaking at the BIO CEO & Investor Conference, US agency's No. 2 official talks about compassionate use, opioids, clinical trial design, and the agency's succession plan.

Advertisement

Related Content

BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking
Gottlieb: The Next Janet Woodcock Is Waiting To Be Discovered At FDA
Gottlieb Adds A No. 2: Sherman Is US FDA Principal Deputy Commissioner
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Off-Label Communication: When Does It Align With Approved Labeling?

Topics

Advertisement
UsernamePublicRestriction

Register

PS122515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel